New York State Common Retirement Fund Sells 2,600 Shares of Moderna, Inc. (NASDAQ:MRNA)

New York State Common Retirement Fund reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 398,132 shares of the company’s stock after selling 2,600 shares during the period. New York State Common Retirement Fund owned approximately 0.10% of Moderna worth $16,554,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB increased its position in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. Venturi Wealth Management LLC increased its position in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the period. Blue Trust Inc. increased its position in Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after buying an additional 388 shares during the period. Finally, EMC Capital Management increased its position in Moderna by 311.2% in the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after buying an additional 946 shares during the period. 75.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on MRNA shares. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Berenberg Bank boosted their price objective on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Wolfe Research started coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Finally, Morgan Stanley lowered their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $60.63.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by corporate insiders.

Moderna Stock Performance

Moderna stock opened at $35.53 on Friday. The firm has a market cap of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59. The business’s fifty day moving average is $38.04 and its two-hundred day moving average is $52.66. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.